Oral supplementation with probiotics, potassium citrate, and magnesium in reducing crystalluria in stone formers: A phase II study.

What Was Tested

This phase 2 clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

Crystalluria is an important indicator of renal stone recurrence.

Mechanisms underlying urinary stone formation are still not fully understood and raising interests has been giving to intestinal commensal bacteria for their contribute in maintaining urinary solutes equilibrium.

Who Took Part

The study group was 2021, patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Since May 2021, the researchers enrolled 23 patients candidates for ureterorenolithotripsy for calcium oxalate kidney stones with crystalluria and a normal metabolic profile.

How the Study Was Run

The analysis was validated by the Institution's Ethical Committee (no. approval STS CE Lazio 1/N-823).

Crystalluria was re-assessed at 1, 3, 6, and 12-months follow-up by polarized light microscopy.

What Was Measured

Mechanisms underlying urinary stone formation are still not fully understood and raising interests has been giving to intestinal commensal bacteria for their contribute in maintaining urinary solutes equilibrium.

The subject headings attached to it are Probiotics, Potassium Citrate, Kidney Calculi, Magnesium, Dietary Supplements, Crystallization and Urine.

The authors tagged it with the keywords calcium oxalate, crystalluria and microbiota.

What This Means in Plain Language

This is a phase 2 clinical trial of Vitamin D, K2, Magnesium and Zinc in 2021, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Urologia), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.